PDF factsheet

Z

immune checkpoint inhibition in lung cancer (metastatic) for first line, clinical trials results

atezolizumab + bevacizumab versus bevacizumab (on top platinum-based CT)
IMpower150 (Teff), 2018 NCT02366143	atezo + bev + C + P versus bev + C + P	chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer and expression of a tumour T-effector gene signature (Teff) and EGFR et ALK negative (wild type)	open label
IMpower150 (WT), 2018 NCT02366143	atezo + bev + C + P; versus bev + C + P	wild type chemotherapy-naïve patients with Stage IV non-squamous non-small cell lung cancer (EGFR et ALK negative)	open label
nivolumab versus platinum-based CT
CheckMate 026, 2016 NCT02041533	Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression versus platinum-based chemotherapy (administered once every 3 weeks for up to six cycles).	patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at >5% (>1%???). Patients with EGFR activating mutations and ALK translocations, which are sensitive to targeted therapy, were excluded.	open design
nivolumab + CT versus platinum-based CT
CheckMate 227 (nivolumab + CT), 2018 NCT02477826	Nivolumab + chemotherapy versus chemotherapy	Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer <1% tumor PD-L1 expression	No masking
nivolumab + ipilimumab versus platinum-based CT
CheckMate 227 (High Tumor Mutational Burden), 2018 NCT02477826	nivolumab plus ipilimumab versus chemotherapy	patients with stage IV or recurrent NSCLC that was not previously treated with chemotherapy and high tumor mutational burden (>=10 mutations per megabase), irrespective of PD-L1 expression level	No masking
pembrolizumab versus platinum-based CT
Keynote 024, 2015 NCT02142738	Pembrolizumab (200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles or until documented PD versus standard of care (SOC) platinum-based chemotherapies	previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene	open label Follow-up duration: 11.2 months (median)
Keynote 042 (>=1%), 2018 NCT02220894	pembrolizumab 200 mg every 3 wk for 35 cycles or until disease progression, intolerable toxicity versus investigator's choice of carboplatin plus paclitaxel or carboplatin plus pemetrexed for a maximum of 6 cycles	Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer	open label Follow-up duration: 12.8-mo median 28 countries in Asia, Canada, Europe, and South America
Keynote 042 (>=20%), 2018 NCT02220894	pembrolizumab versus SOC Treatment (Platinum-based Chemotherapy)	Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer	open label Follow-up duration: 12.8-mo median china
Keynote 042 (>=50%), 2018 NCT02220894	pembrolizumab versus SOC Treatment (Platinum-based Chemotherapy)	Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer	open label Follow-up duration: 12.8-mo median china
pembrolizumab + platinum-based CT versus platinum-based CT
Keynote 189, 2018 NCT02578680	pemetrexed and a platinum-based drug plus 200 mg of pembrolizumab, followed by pembrolizumab for up to a total of 35 cycles plus pemetrexed maintenance therapy versus pemetrexed and a platinum-based drug plus placebo every 3 weeks for 4 cycles, followed by placebo	participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and without sensitizing EGFR or ALK mutations	double-blind Follow-up duration: 10.5 mo median
KEYNOTE-021 phase 2, 2016 NCT02039674	24 months treatment with pembrolizumab (200mg every three weeks)+ CT versus four cycles of carboplatin and pemetrexed (500 mg/m2 every three weeks)	patients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer	open design

Options

Group by
in first

in second

Order trials by

Filter

display ongoing trials

Type of trial

Limit to tags

Exclude tags